We provide you with 20 years of free, institutional-grade data for NVAX stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of NVAX. Explore the full financial landscape of NVAX stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| King Rachel K. | Derivatives Exercise | 18,880 | 2026-06-23 | ||
| DOUGLAS RICHARD | Derivatives Exercise | 18,880 | 2026-06-23 | ||
| MCGLYNN MARGARET G | Derivatives Exercise | 18,880 | 2026-06-23 | ||
| MOTT DAVID M | Derivatives Exercise | 18,880 | 2026-06-23 | ||
| Alton Gregg H | Derivatives Exercise | 18,880 | 2026-06-23 | ||
| Rodgers Richard J | Derivatives Exercise | 18,880 | 2026-06-23 | ||
| Newton Charles W. | Derivatives Exercise | 9,520 | 2026-04-28 | ||
| Walker Robert Edward | Initial | 2026-04-16 | |||
| Shiver John W. | Derivatives Exercise | 7,947 | 2026-03-12 | ||
| Kelly James Patrick | Sale | -5,904 | $9.98 | $58,922 | 2026-03-09 |
| Kelly James Patrick | Derivatives Exercise | 12,223 | 2026-03-09 | ||
| Kelly James Patrick | Sale | -20,850 | $9.49 | $197,867 | 2026-03-05 |
| Kelly James Patrick | Derivatives Exercise | 43,167 | 2026-03-05 | ||
| Jacobs John C | Sale | -69,288 | $9.49 | $657,543 | 2026-03-05 |
| Jacobs John C | Derivatives Exercise | 150,167 | 2026-03-05 | ||
| O'Hara Elaine | Sale | -22,429 | $9.49 | $212,851 | 2026-03-05 |
| O'Hara Elaine | Derivatives Exercise | 56,334 | 2026-03-05 | ||
| Casey Mark J | Sale | -11,378 | $9.49 | $107,977 | 2026-03-05 |
| Casey Mark J | Derivatives Exercise | 37,500 | 2026-03-05 | ||
| Draghia-Akli Ruxandra | Sale | -11,313 | $9.49 | $107,360 | 2026-03-05 |
| Draghia-Akli Ruxandra | Derivatives Exercise | 26,667 | 2026-03-05 | ||
| Jacobs John C | Sale | -38,450 | $10.14 | $389,883 | 2026-03-03 |
| Jacobs John C | Derivatives Exercise | 83,333 | 2026-03-03 | ||
| Kelly James Patrick | Sale | -28,366 | $10.14 | $287,631 | 2026-03-03 |
| Kelly James Patrick | Derivatives Exercise | 58,666 | 2026-03-03 | ||
| O'Hara Elaine | Sale | -16,344 | $10.14 | $165,728 | 2026-03-03 |
| O'Hara Elaine | Derivatives Exercise | 59,600 | 2026-03-03 | ||
| Casey Mark J | Sale | -1,214 | $10.14 | $12,310 | 2026-03-03 |
| Casey Mark J | Derivatives Exercise | 4,000 | 2026-03-03 | ||
| Jacobs John C | Sale | -39,132 | $9.17 | $358,840 | 2026-01-26 |
| Jacobs John C | Derivatives Exercise | 83,197 | 2026-01-26 | ||
| Casey Mark J | Sale | -12,713 | $6.69 | $85,050 | 2025-12-15 |
| Casey Mark J | Derivatives Exercise | 41,899 | 2025-12-15 | ||
| Draghia-Akli Ruxandra | Sale | -6,048 | $7.4 | $44,755 | 2025-11-13 |
| Draghia-Akli Ruxandra | Derivatives Exercise | 14,257 | 2025-11-13 | ||
| Rodgers Richard J | Derivatives Exercise | 3,800 | 2025-10-30 | ||
| MCGLYNN MARGARET G | Derivatives Exercise | 10,420 | 2025-06-16 | ||
| Alton Gregg H | Derivatives Exercise | 10,420 | 2025-06-16 | ||
| Rodgers Richard J | Derivatives Exercise | 10,420 | 2025-06-13 | ||
| King Rachel K. | Derivatives Exercise | 10,420 | 2025-06-13 | ||
| MOTT DAVID M | Derivatives Exercise | 10,420 | 2025-06-13 | ||
| DOUGLAS RICHARD | Derivatives Exercise | 10,420 | 2025-06-13 | ||
| Kelly James Patrick | Sale | -5,904 | $8.34 | $49,239 | 2025-03-11 |
| Kelly James Patrick | Derivatives Exercise | 12,223 | 2025-03-11 | ||
| Trizzino John | Sale | -13,954 | $8.34 | $116,376 | 2025-03-11 |
| Trizzino John | Derivatives Exercise | 28,890 | 2025-03-11 | ||
| Trizzino John | Sale | -23,185 | $8.33 | $193,131 | 2025-03-04 |
| Trizzino John | Derivatives Exercise | 48,000 | 2025-03-04 | ||
| Casey Mark J | Sale | -1,214 | $8.33 | $10,113 | 2025-03-04 |
| Casey Mark J | Derivatives Exercise | 4,000 | 2025-03-04 | ||
| Kelly James Patrick | Sale | -28,337 | $8.33 | $236,047 | 2025-03-04 |
| Kelly James Patrick | Derivatives Exercise | 58,667 | 2025-03-04 | ||
| Jacobs John C | Sale | -38,451 | $8.33 | $320,297 | 2025-03-04 |
| Jacobs John C | Derivatives Exercise | 83,334 | 2025-03-04 | ||
| O'Hara Elaine | Sale | -16,344 | $8.33 | $136,146 | 2025-03-04 |
| O'Hara Elaine | Derivatives Exercise | 59,600 | 2025-03-04 | ||
| Alton Gregg H | Grant, award...etc | 7,915 | $4.9 | 2025-02-05 | |
| MCGLYNN MARGARET G | Grant, award...etc | 4,698 | $4.9 | 2025-02-05 | |
| Jacobs John C | Sale | -38,873 | $9.55 | $371,237 | 2025-01-27 |
| Jacobs John C | Derivatives Exercise | 83,196 | 2025-01-27 | ||
| Kelly James Patrick | Sale | -16,906 | $8.04 | $135,924 | 2025-01-03 |
| Kelly James Patrick | Derivatives Exercise | 35,000 | 2025-01-03 | ||
| King Rachel K. | Sale | -4,150 | $9.02 | $37,435 | 2025-01-02 |
| YOUNG JAMES F | Sale | -10,000 | $8.48 | $84,800 | 2025-01-02 |
| Rodgers Richard J | Derivatives Exercise | 3,800 | 2025-01-02 | ||
| Casey Mark J | Sale | -12,713 | $8.82 | $112,129 | 2024-12-13 |
| Casey Mark J | Derivatives Exercise | 41,900 | 2024-12-13 | ||
| Trizzino John | Sale | -317 | $13.9 | $4,406 | 2024-08-21 |
| Trizzino John | Derivatives Exercise | 655 | 2024-08-21 | ||
| Kelly James Patrick | Sale | -1,223 | $12.96 | $15,850 | 2024-08-20 |
| Kelly James Patrick | Derivatives Exercise | 2,367 | 2024-08-20 | ||
| YOUNG JAMES F | Sale | -7,500 | $14.09 | $105,675 | 2024-06-25 |
| YOUNG JAMES F | Sale | -7,500 | $13.62 | $102,150 | 2024-06-21 |
| Dubovsky Filip | Sale | -13,904 | $14.46 | $201,052 | 2024-06-20 |
| Dubovsky Filip | Derivatives Exercise | 13,904 | 2024-06-20 | ||
| MOTT DAVID M | Derivatives Exercise | 6,670 | 2024-06-14 | ||
| Rodgers Richard J | Derivatives Exercise | 6,670 | 2024-06-14 | ||
| YOUNG JAMES F | Derivatives Exercise | 6,670 | 2024-06-14 | ||
| DOUGLAS RICHARD | Derivatives Exercise | 6,670 | 2024-06-14 | ||
| King Rachel K. | Derivatives Exercise | 6,670 | 2024-06-14 | ||
| Alton Gregg H | Derivatives Exercise | 6,670 | 2024-06-14 | ||
| MCGLYNN MARGARET G | Derivatives Exercise | 6,670 | 2024-06-14 | ||
| Dubovsky Filip | Sale | -47,312 | $13.9 | $657,637 | 2024-05-15 |
| Dubovsky Filip | Derivatives Exercise | 19,652 | 2024-05-15 | ||
| Kelly James Patrick | Sale | -2,226 | $5.45 | $12,132 | 2024-03-12 |
| Kelly James Patrick | Derivatives Exercise | 4,608 | 2024-03-12 | ||
| Trizzino John | Sale | -2,226 | $5.45 | $12,132 | 2024-03-12 |
| Trizzino John | Derivatives Exercise | 4,608 | 2024-03-12 | ||
| Dubovsky Filip | Sale | -2,597 | $5.45 | $14,154 | 2024-03-12 |
| Dubovsky Filip | Derivatives Exercise | 5,376 | 2024-03-12 | ||
| Kelly James Patrick | Sale | -5,905 | $5.61 | $33,127 | 2024-03-11 |
| Kelly James Patrick | Derivatives Exercise | 12,224 | 2024-03-11 | ||
| Trizzino John | Sale | -13,955 | $5.61 | $78,288 | 2024-03-11 |
| Trizzino John | Derivatives Exercise | 28,890 | 2024-03-11 | ||
| Dubovsky Filip | Sale | -9,392 | $5.61 | $52,689 | 2024-03-11 |
| Dubovsky Filip | Derivatives Exercise | 19,444 | 2024-03-11 | ||
| O'Hara Elaine | Sale | -5,375 | $5.39 | $28,971 | 2024-03-05 |
| O'Hara Elaine | Derivatives Exercise | 19,600 | 2024-03-05 | ||
| Jacobs John C | Sale | -40,093 | $4.26 | $170,796 | 2024-01-25 |
| Jacobs John C | Derivatives Exercise | 83,197 | 2024-01-25 | ||
| Dubovsky Filip | Sale | -1,368 | $5.69 | $7,784 | 2023-12-18 |
| Dubovsky Filip | Derivatives Exercise | 2,833 | 2023-12-18 | ||
| Trizzino John | Sale | -773 | $5.69 | $4,398 | 2023-12-18 |
| Trizzino John | Derivatives Exercise | 1,600 | 2023-12-18 | ||
| Herrmann John A III | Sale | -700 | $5.69 | $3,983 | 2023-12-18 |
| Herrmann John A III | Derivatives Exercise | 2,100 | 2023-12-18 |
The information provided in this report about NVAX stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Novavax, Inc(NASDAQ:NVAX) 
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one...
Website: http://www.novavax.com
Founded: 1987
Full Time Employees: 522
CEO: Stanley C. Erck
Sector: Healthcare
Industry: Biotechnology